| Scientific/Clinical Member Nominations are Now Being Accepted for the Department of Health and Human Services (HHS) Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV  The HHS Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (or the Panel) is accepting nominations for new scientific/clinical members with expertise in HIV medicine. The Panel is seeking candidates with expertise in: - pharmacology of antiretrovirals in children and adolescents
- clinical use of antiretrovirals in infants and children, and/or
- children with HIV transitioning into adolescence and young adulthood.
Individuals who served as Panel members in the past are welcome to reapply. Panel members critically evaluate new information and prepare guidelines revisions. The candidates should be recognized experts in their areas of interest. The successful candidates will serve a 3-year term beginning April 2022, with potential for reappointment for an additional term. The Panel is a Working Group of the Office of AIDS Research Advisory Council of the National Institutes of Health. The Panel is composed of approximately 30 members who are clinicians, researchers, academicians, HHS representatives, and community representatives with expertise in HIV management in the United States. The Panel meets monthly via teleconferencing to review and critically evaluate emerging scientific data relating to antiretroviral therapy in children and revise the Guidelines for Use of Antiretroviral Agents in Pediatric HIV Infection, which are found at https://clinicalinfo.hiv.gov/en. In addition, an Antiretroviral Subgroup meets monthly. Those with pharmacologic expertise would be expected to attend both meetings. Panel members are not financially compensated for their time commitment. The nomination should include a curriculum vitae and a letter of interest or a letter of nomination with specific reference to how the nominee would contribute to the work of the Panel. Self-nomination is welcome. All supporting documents should be submitted to Segun Adeyemi, Guidelines Coordinator at segun.adeyemi@nih.gov no later than February 28, 2022. | | | Community Member Nominations are Now Being Accepted for the Department of Health and Human Services (HHS) Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV The HHS Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (or the Panel) is accepting nominations for a new community representative to serve a 3-year term beginning April 2022 with potential for reappointment. Individuals who served as Panel members in the past are welcome to reapply. The Panel welcomes diversified representation in the community membership reflecting the demographics of the current HIV epidemic in the United States. The community member may assist the Panel in identifying and addressing unique treatment aspects that relate to the constituency they represent. The candidate shall have knowledge and involvement in issues related to management of HIV-infected children and adolescents, as evidenced by experience in HIV treatment education/advocacy or clinical/public policy initiatives related to HIV treatment. The Panel is a Working Group of the Office of AIDS Research Advisory Counsel of the National Institutes of Health. The Panel is composed of over 30 members who are clinicians, researchers, academicians, HHS representatives, and community representatives with expertise in HIV management in the United States. The Panel meets monthly via teleconferencing to review and critically evaluate emerging scientific data relating to antiretroviral therapy and revise the Guidelines for Use of Antiretroviral Agents in Pediatric HIV Infection, which are found at https://clinicalinfo.hiv.gov/en. Panel members are not compensated for their time commitment. The nomination should include a curriculum vitae and a letter of interest or a letter of nomination with specific reference to how the nominee would contribute to the work of the Panel. Self-nomination is welcome. All supporting documents should be submitted to Segun Adeyemi, Guidelines Coordinator at segun.adeyemi@nih.gov no later than February 28, 2022. | | | |
No comments:
Post a Comment